Clinical Trial Update: Iparomlimab and Tuvonralimab (QL1706) Combined With Standard Chemotherapy or Combined With Intraperitoneal Perfusion Chemotherapy and Olaparib as Neoadjuvant Therapy for Advanced Ovarian Cancer [Phase 2]

View source ↗

Summary

A Phase 2 neoadjuvant trial in advanced ovarian cancer evaluating iparomlimab and tuvonralimab (QL1706) with either standard chemotherapy or intraperitoneal per…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Olaparib (Olaparib)
• Tuvonralimab (tuvonralimab)
• iparomlimab

Snippet

Sponsor: Jiangsu Cancer Institute & Hospital | Conditions: Ovarian Cancers | Phase 2 | Status: NOT_YET_RECRUITING